Alkyne as a Latent Warhead to Covalently Target SARS-CoV-2 Main Protease
Chau Ngo, William A. Fried, Saba Roghiyh Aliyari, Joshua J. Feng, Chao Qin, Shilei Zhang, Hanjing Yang, Jean Shanaa, Pinghui Feng, Genhong Cheng, Xiaojiang S. Chen, Chao Zhang · Journal of Medicinal Chemistry · 2023
High Resolution Image Download MS PowerPoint Slide There is an urgent need for improved therapy to better control the ongoing COVID-19 pandemic. The main protease M pro plays a pivotal role in SARS-CoV-2 replications, thereby representing an attractive target for antiviral development. We seek to identify novel electrophilic warheads for efficient, covalent inhibition of M pro . By comparing the efficacy of a panel of warheads installed on a common scaffold against M pro, we discovered that the terminal alkyne could covalently modify M pro as a latent warhead. Our biochemical and X-ray structural analyses revealed the irreversible formation of the vinyl-sulfide linkage between the alkyne and the catalytic cysteine of M pro . Clickable probes based on the alkyne inhibitors were developed to measure target engagement, drug residence time, and off-target effects. The best alkyne-containing inhibitors potently inhibited SARS-CoV-2 infection in cell infection models. Our findings highlight great potentials of alkyne as a latent warhead to target cystine proteases in viruses and beyond.